SOHO 2021 | The extension of survival at relapse

At the current time, I think that the paradigm for the management of prolapsing refractory myeloma patients is quite exciting because plenty of drugs with the different mechanism of action and novel agents are emerging, and this is clearly impacting in the overall survival. And to that, we have always to try to utilize the best combinations at the beginning because more patients are going to benefit and the benefit is going to be superior, but we have to acknowledge the introduction of many novel combinations and many novel approaches of therapy at the relapse and on refractory situation, because they are going to be the responsible of the prolongation in the overall survival we are observing in the management of patients with multiple myeloma.

In addition, some of these novel strategies that are being utilized right now at the latest advanced stage of the disease or at the moment of the relapse, we’ll rapidly move to early lines of therapy even into the after all setting, and definitely the benefit is going to be superior. And I think that at the end of the day, the overall survival of our myeloma patients is significantly improving in comparison with the survival we had some years ago. And this is basically based on the introduction of very effective combinations in the after all settings, but also because rescue therapies are becoming available for patients such subsequent relapses.